About Us

Luye Pharma Group (02186.HK), a member of Luye Life Sciences Group, is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications.

Luye Pharma’s Innovative Drug Zepzelca® (Lurbinectedin) Launched in Hong Kong and Macao

News

- Reshaping the landscape for the second-line treatments of Small Cell Lung Cancer - Hong Kong and Macao, March 7, 2024 – A symposium called the New Treatment Paradigm for Small Cell Lung Cancer (SCLC) organized by the Hong Kong Cancer ...

March 07,2024

First Patient Enrolled for Phase 3 Clinical Study of Luye Pharma’s Irinotecan Hydrochloride Liposome Injection (LY01610)

Shanghai, March 4, 2024 – Luye Pharma Group announced today that the first patient has been enrolled for a Phase 3 clinical trial of its investigational anticancer drug Irinotecan Hydrochloride Liposome Injection (LY01610). This is a ...

March 04,2024

Read More

Investors

Employee Stories

Upholding the philosophy of “Employee Development”,
Luye Pharma regards employees as the most valuable resources of the company